Omeros Corporation (OMER) News
Track canonical SquawkNews coverage tagged to OMER, Omeros Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Natera hits Japan regulatory approval milestone; Omeros reaches 5-year peak
Natera shares rose after Japan regulatory approval for its cancer test; Omeros shares gained after a Cantor Fitzgerald upgrade and optimism around its lead drug’s commercialization.
EQUITY | Sep 22, 2026, 05:51 PM UTC
H
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 1% on Monday. Shares of On Holding AG (NYSE: ONON ) rose sharply after the company affirmed its FY26 sales guidance above estimates and issued third-quarter
LIVE | Sep 22, 2026, 02:25 PM UTC
M
Cantor Fitzgerald upgrades Omeros to Overweight; $22 target
Cantor Fitzgerald upgraded Omeros to Overweight and set a $22.00 price target, implying 19.0% upside versus the Sep 21 close of $18.49.
EQUITY | Sep 22, 2026, 10:50 AM UTC
L
Omeros VP General Counsel sold shares worth $929,667
Peter B. Cancelmo, VP and General Counsel at Omeros, sold common stock in two transactions at weighted average prices of $18.6451 and $18.5416 per share, totaling $929,667.
EQUITY | Sep 01, 2026, 08:51 PM UTC
L
Premarket gainers list led by GXAI, CURI and IVDA
A premarket movers list shows GXAI, CURI, IVDA, HLIT, OMER, FGI, BIVI, FRGT, ONDG and HHS among the top percentage gainers, with no catalyst supplied.
EQUITY | Aug 13, 2026, 09:43 AM UTC
L
Omeros shares rise after second-quarter earnings beat estimates
Omeros Corp. shares rise in pre-market trading after the company reported second-quarter earnings of 2 cents per share and sales of $28.529 million, both above analyst estimates.
EARNINGS | Aug 13, 2026, 09:16 AM UTC
L
Omeros Q2 Adj. EPS Beats Estimate
Omeros reports Q2 adjusted EPS of $0.02, beating the estimate of $(0.27)
EARNINGS | Aug 12, 2026, 08:09 PM UTC
H
US: Omeros Corp Gets NTAP Status for Yartemlea
Omeros Corp gets NTAP status for Yartemlea
EQUITY | Aug 03, 2026, 12:33 PM UTC
L
OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopath
OMER shares up 10% on day in reaction to AZN PH3 failure of Ultomiris (ravulizumab) to treat transplant-associated thrombotic microangiopathy. Note Omeros markets Yartemlea (narsoplimab), which is approved for hematopoie
EQUITY | Jul 27, 2026, 04:09 PM UTC
H
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
The major averages were mixed near noon, with the Dow higher and the S&P 500 and Nasdaq in decline amid weakness in tech stocks. Still, the market has reacted positively to easing geopolitical tensions and a steep declin
MACRO | Jul 27, 2026, 03:56 PM UTC
L
Omeros up 11% to $10.89 after AstraZeneca study failure
Omeros up 11% to $10.89 after AstraZeneca study failure
EQUITY | Jul 27, 2026, 02:13 PM UTC
L
OMER EMA: upon receipt of grounds of Omeros Ireland's request, will Re-examine opinion on yartemlea & issue final recommendation
OMER EMA: upon receipt of grounds of Omeros Ireland's request, will Re-examine opinion on yartemlea & issue final recommendation
EQUITY | Jul 15, 2026, 12:37 PM UTC
L
OMER EMA: Omeros Ireland requested Re-examination of EMA's opinion on yartemlea issued on 25 June - website
OMER EMA: Omeros Ireland requested Re-examination of EMA's opinion on yartemlea issued on 25 June - website
EQUITY | Jul 15, 2026, 12:36 PM UTC
L
Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About
NEW YORK CITY, NY / / July 3, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on
EQUITY | Jul 03, 2026, 03:01 PM UTC
H
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers INVO Fertility (NASDAQ: IVF ) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings came out 4 days ag
EARNINGS | Jun 26, 2026, 05:05 PM UTC
H
Oil Falls 4%
Crude oil prices fall 4% to $69.05, while US consumer sentiment rises to 49.5 in June
COMMODITIES | Jun 26, 2026, 04:17 PM UTC
H
OMER: EMA Rejects Narsoplimab
The European Medicines Agency's Human Medicines Committee issues a negative opinion for Omeros Corp.'s narsoplimab for stem cell transplant-associated thrombotic microangiopathy
EQUITY | Jun 26, 2026, 03:16 PM UTC
M
OMER Updates EU Application
Omeros Corporation announces update on European marketing authorization application for Narsoplimab in TA-TMA
EQUITY | Jun 26, 2026, 12:38 PM UTC
H
OMER Gets EMA CHMP Negative Opinion
Omeros Corporation receives a negative opinion from the EMA CHMP on its marketing authorization application for narsoplimab in TA-TMA
REGULATION | Jun 26, 2026, 12:33 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Friday's pre-market session, with gainers including Quantum Cyber and INVO Fertility, and losers including Creative Medical Tech and Omeros
EQUITY | Jun 26, 2026, 12:05 PM UTC